The DOI matches its Crossref record; 250 of the 263 references it cites were found in a registry or an index; 169 of the 250 sources its claims cite were checked for support.
Senescence and cancer — role and therapeutic opportunities
Open accessAbstract
Cellular senescence is a state of stable, terminal cell cycle arrest associated with various macromolecular changes and a hypersecretory, pro-inflammatory phenotype. Entry of cells into senescence can act as a barrier to tumorigenesis and, thus, could in principle constitute a desired outcome for any anticancer therapy. Paradoxically, studies published in the past decade have demonstrated that, in certain conditions and contexts, malignant and non-malignant cells with lastingly persistent senescence can acquire pro-tumorigenic properties. In this Review, we first discuss the major mechanisms involved in the antitumorigenic functions of senescent cells and then consider the cell-intrinsic and cell-extrinsic factors that participate in their switch towards a tumour-promoting role, providing an overview of major translational and emerging clinical findings. Finally, we comprehensively describe various senolytic and senomorphic therapies and their potential to benefit patients with cancer.
Overview
CoChat Summary
# TL;DR
This is a narrative review arguing that cellular senescence has a dual role in cancer: it can suppress tumor initiation and aid immune clearance, but persistent senescent cells can also promote relapse, metastasis, and treatment toxicity through the SASP. The authors conclude that senolytic and senomorphic strategies are promising, but clinical evidence is still limited and the best therapeutic window and dosing remain unresolved.
# Key findings
- Senescence is described as a natural barrier to tumorigenesis and is “widely detected in premalignant lesions” from patients with cancer, supporting a tumor-suppressive role.
- The review states that anticancer therapy induces senescence and that this can contribute to treatment-related adverse events such as fatigue, frailty, cardiac dysfunction, hepatic failure, renal failure, inflammation, bone loss, and muscle weakness.
- Senescent cells can also promote cancer progression through SASP-mediated effects including chronic inflammation, mitogenic signaling, stemness, angiogenesis, migration and invasion, genotoxicity, and immunosuppression.
- Therapeutic targeting of senescence is presented as promising: senolytics remove senescent cells, while senomorphics reduce SASP; however, the paper says prospective results of large-cohort oncology trials “remain to be reported.”
# Methods
- Narrative review / expert synthesis in *Nature Reviews Clinical Oncology* rather than an original experimental study.
- The authors “researched data for the article” and built the review from published preclinical and clinical studies across cancer biology, therapy-induced senescence, and senotherapeutics.
- Main analysis is qualitative and mechanistic: the paper compares antitumor versus protumor roles of senescence, then surveys translational and emerging clinical findings on senolytics and senomorphics.
# Limitations
- The paper explicitly notes that no dependable quantitative assessment can currently separate the long-term contributions of senescence’s beneficial and detrimental effects in patients, and marker-based detection/targeting of senescent subpopulations is not yet feasible in the clinic.
- It also says that while many candidate senolytics are promising and some have entered clinical trials, “prospective results of large-cohort oncology trials remain to be reported.”
- Evident from the text: this is a review synthesizing heterogeneous preclinical and correlative human studies, so many conclusions are based on indirect evidence and the paper does not report a new dataset or primary outcome of its own.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
110 Valid · 7 Not valid · 41 Not checked · 50 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In mice harbouring a Braf V600E mutation and Pten loss, deletion of Atg7 , another autophagy- related gene, facilitates melanoma formation by disabling senescence 46 .”
What the sources say
- Disputedcites [46] Xie, X., Koh, J. Y., Price, S., White, E. & Mehnert, J. M. Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma. Cancer Discov. 5, 410–423 (2015). sourceExperimental — accuracy not yet measured
The Results section on Pten-deficient melanomas reports that deleting both Atg7 alleles profoundly suppressed tumor growth rather than facilitating melanoma formation. The Results section on senescence reports that Atg7 deficiency increased senescence markers; it was ATG7 expression that suppressed senescence. Page numbers are not provided in our copy. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Clearance of senescent cells during ageing extends the lifespan and healthspan of aged transgenic mice 20”
What the sources say
- Supportedcites [20] Baker, D. J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016). source
The Abstract reports that clearing p16Ink4a-positive cells in INK-ATTAC mice extended median lifespan and attenuated age-related deterioration in several organs. The section “p16Ink4a-positive cells shorten lifespan and healthspan” reports 24% and 27% increases in median lifespan in the two treated cohorts. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In aged organisms, senescent cells can contribute to a variety of age- related pathologies, including pulmonary fibrosis, biliary liver damage, arteriosclerosis, retinopathy, osteoarthritis, dementia and diabetes mellitus 13-19 .”
What the sources say
- Not checked — no full text of the sourcecites [13] Minamino, T. et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat. Med. 15, 1082–1087 (2009). source
- Partly supportedcites [14] Childs, B. G. et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 354, 472–477 (2016). sourceExperimental — accuracy not yet measured
The paper’s Abstract reports that senescent cells drive atherosclerosis in susceptible mice, supporting the arteriosclerosis example. It does not address the other listed pathologies or establish the claim specifically for aged organisms. (LLM, conf=0.86)
- Supportedcites [15] Jeon, O. H. et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat. Med. 23, 775–781 (2017). source
In this group of citations, Jeon et al. supports the osteoarthritis example. The main text (age-related OA paragraph, Fig. 3a–c; page not provided) reports that clearing naturally occurring senescent cells reduced age-related cartilage degeneration in mice. (LLM, conf=0.91)
- Supportedcites [16] Schafer, M. J. et al. Cellular senescence mediates fibrotic pulmonary disease. Nat. Commun. 8, 14532 (2017). source
The Discussion states that cellular senescence contributes to fibrotic lung disease. This paper supports the pulmonary-fibrosis example in the sentence’s citation range; the other listed conditions are not attributed specifically to this source. (LLM, conf=0.92)
- Partly supportedcites [17] Bussian, T. J. et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 562, 578–582 (2018). sourceExperimental — accuracy not yet measured
The paper’s opening passage says senescent cells contribute to atherosclerosis and osteoarthritis, and its tauopathy mouse study links senescent glial cells to cognitive decline. It does not address pulmonary fibrosis, biliary liver damage, retinopathy, or diabetes mellitus; nor does the mouse finding establish a contribution to dementia in aged organisms. No page number is available in our copy. (LLM, conf=0.88)
- Supportedcites [18] Ferreira-Gonzalez, S. et al. Paracrine cellular senescence exacerbates biliary injury and impairs regeneration. Nat. Commun. 9, 1020 (2018). source
The Discussion reports that cellular senescence is likely to drive biliary injury and impair liver regeneration. In this multi-citation list, the source supports the biliary liver damage example; the other listed pathologies are not attributed to it individually. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [19] Binet, F. et al. Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy. Science 369, eaay5356 (2020). source
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“In PTEN - loss invitro models of induced senescence, the activated mTOR kinase in mTORC1 or mTORC2 stabilizes p53 and triggers the senescent state 39 .”
What the sources say
- Supportedcites [39] Jung, S. H. et al. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53. Oncogene 38, 1639–1650 (2019). source
The Discussion reports that mTOR stabilizes p53 through its kinase activity in PTEN-depleted cells and PTEN-knockout mouse embryonic fibroblasts, switching cell fate to premature senescence. It also states that both mTORC1 and mTORC2 mediate p53-dependent senescence in the absence of PTEN. Page numbers are not provided in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The presence of senescent human- derived cultured cells limits fibrosis during skin wound healing 9”
What the sources say
- Partly supportedcites [9] Jun, J.-I. & Lau, L. F. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat. Cell Biol. 12, 676–685 (2010). sourceExperimental — accuracy not yet measured
The Results section ('CCN1-regulated senescence restricts fibrosis in cutaneous wound healing'; page unavailable) reports that senescent cells accumulated in mouse wounds and that CCN1-induced senescence curtailed collagen deposition. The paper also studied cultured human fibroblasts, but it does not show that those human-derived cultured cells were present in healing wounds or limited fibrosis there. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
127 more claims · 68 with their cited sources checked
Create a free account to see all 208 claims and to verify the 3 references still open.
- It may state two separate claims as one. 65
- Probably not a substantial claim. 14
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876
Hallmarks of Cellular Senescence
Hernandez-Segura, A., Nehme, J., & Demaria, M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.02.001 · Cited by 2,605
Self-citationThe Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Senolytics improve physical function and increase lifespan in old age
Xu, M., Pirtskhalava, T., Farr, J. N., Weigand, B. M., Palmer, A. K., Weivoda, M. M., Inman, C. L., Ogrodnik, M. B., Hachfeld, C. M., Fraser, D. G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0092-9 · Cited by 2,287
Research works printed but not linked: 1
- te Poele, R. H., Okorokov, A. L., Jardine, L., Cummings, J. & Joel, S. P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 62, 1876–1883 (2002).
Cited by
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
“In the therapy-induced senescence model, cells undergoing senescence regain proliferative properties through reversibility of senescence, or acquire senescence-associated stemness by reprogramming mechanisms and turn into highly aggressive tumors, which drive tumor recurrence and progression.(485) Therefore, there may…”
BackgroundInfluentialBreast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
The senescence-associated secretory phenotype and its physiological and pathological implications
Wang, B., Han, J., Elisseeff, J. H., & Demaria, M. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00727-x · Cited by 948
“…proliferation arrest; oncogene-induced senescence (OIS) 3 , for cells overexpressing an onco-gene, primarily RAS; therapy-induced senescence (TIS) 4,5 , for cells exposed to high but non-lethal doses of drugs or chemicals; mitochondrial dysfunction-induced senescence (MiDAS) 6 , for cells…”
InfluentialSelf-citationTumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01848-7 · Cited by 399
“228 Moreover, mutations in the promoter of TERT, which allow for the maintenance of telomeres, are one of the most common driver mutations in a variety of tumors, and can be detected even in cirrhotic regenerative nodules, preventing cellular senescence and cell-cycle arrest, and thereby enhancing…”
Background
Metadata
- Authors
- Schmitt, C. A., Wang, B., & Demaria, M.
- Affiliations
- Johannes Kepler University of Linz (AT)
- University Medical Center Groningen (NL)
- Corresponding author
- Demaria, Marco
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2022-08-31
- Volume
- 19
- Issue
- 10
- Pages
- 619-636
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- PMC
- PMC9428886
- OpenAlex
- W4293747103
- Cited by
- 794
- References
- 263
- Citations by year
- 2026: 130 · 2025: 274 · 2024: 249 · 2023: 105 · 2022: 8
- FWCI
- 27.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- cellular senescence, cancer, carcinogenesis, senescence-associated secretory phenotype, senescence-associated inflammation, senolytic therapy, cell cycle arrest
- MeSH terms
- Senotherapeutics, Humans, Neoplasms, Cellular Senescence, Cell Cycle Checkpoints, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Senescence and cancer — role and therapeutic opportunities. https://app.cochat.ai/papers/10.1038/s41571-022-00668-4
- The paper
- Schmitt, C. A., Wang, B., & Demaria, M. (2022). Senescence and cancer — role and therapeutic opportunities. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-022-00668-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.